Key results of the different currently available PI3K inhibitors
| Drug . | Disease characteristics . | Number of patients (total/follicular) . | ORR . | CRR . | PFS, median (mo) . | DOR, median (mo) . | 2-y OS . | Most common grade 3-4 adverse events (present in ≥5% of patients)* . |
|---|---|---|---|---|---|---|---|---|
| Idelalisib27,28 | Double refractory to rituximab and alkylating agents | 72/125 | 66%† | 14%† | 11 (11†) | 12 (11†) | 70%† | Neutropenia (27%) |
| ALT elevation (13%) | ||||||||
| Diarrhea (13%) | ||||||||
| Pneumonia (7%) | ||||||||
| Thrombocytopenia (6%) | ||||||||
| Duvelisib14 | Double refractory to rituximab and alkylating agents | 129/83 | 42%† | 1%† | 10 | 10 | ∼60%‡ | Neutropenia (25%) |
| Diarrhea (15%) | ||||||||
| Anemia (15%) | ||||||||
| Thrombocytopenia (12%) | ||||||||
| Febrile neutropenia (9%) | ||||||||
| Lipase increased (7%) | ||||||||
| ALT elevation (5%) | ||||||||
| Pneumonia (5%) | ||||||||
| Colitis (5%) | ||||||||
| Copanlisib29 | Relapsed or refractory after 2 lines of therapy | 142/104 | 59%† | 20%† | 13 | 14 | 69% augment | Hyperglycemia (40%) |
| Hypertension (24%) | ||||||||
| Neutropenia (24%) | ||||||||
| Pneumonia (11%) | ||||||||
| Diarrhea (9%) | ||||||||
| Anemia (5%) | ||||||||
| Thrombocytopenia (5%) |
| Drug . | Disease characteristics . | Number of patients (total/follicular) . | ORR . | CRR . | PFS, median (mo) . | DOR, median (mo) . | 2-y OS . | Most common grade 3-4 adverse events (present in ≥5% of patients)* . |
|---|---|---|---|---|---|---|---|---|
| Idelalisib27,28 | Double refractory to rituximab and alkylating agents | 72/125 | 66%† | 14%† | 11 (11†) | 12 (11†) | 70%† | Neutropenia (27%) |
| ALT elevation (13%) | ||||||||
| Diarrhea (13%) | ||||||||
| Pneumonia (7%) | ||||||||
| Thrombocytopenia (6%) | ||||||||
| Duvelisib14 | Double refractory to rituximab and alkylating agents | 129/83 | 42%† | 1%† | 10 | 10 | ∼60%‡ | Neutropenia (25%) |
| Diarrhea (15%) | ||||||||
| Anemia (15%) | ||||||||
| Thrombocytopenia (12%) | ||||||||
| Febrile neutropenia (9%) | ||||||||
| Lipase increased (7%) | ||||||||
| ALT elevation (5%) | ||||||||
| Pneumonia (5%) | ||||||||
| Colitis (5%) | ||||||||
| Copanlisib29 | Relapsed or refractory after 2 lines of therapy | 142/104 | 59%† | 20%† | 13 | 14 | 69% augment | Hyperglycemia (40%) |
| Hypertension (24%) | ||||||||
| Neutropenia (24%) | ||||||||
| Pneumonia (11%) | ||||||||
| Diarrhea (9%) | ||||||||
| Anemia (5%) | ||||||||
| Thrombocytopenia (5%) |
ALT, alanine transaminase; CRR, complete response rate; DOR, duration of response; ORR, overall response rate; OS, overall survival.
*Collected on all patients analyzed in the study.
†Patients with follicular lymphoma only.
‡Estimated from OS curve.